Welcome to our dedicated page for Assertio Holdings SEC filings (Ticker: ASRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Assertio Holdings, Inc. (ASRT) provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Assertio’s operations as a pharmaceutical company focused on oncology, neurology, and pain management, and they complement the company’s press releases and investor presentations.
Through this page, readers can review current reports on Form 8-K, where Assertio reports material events such as leadership transitions, executive appointments, supply and licensing agreements, and financial results announcements. For example, recent 8-K filings describe the appointment of a new Chief Executive Officer, the promotion of a President and Chief Operating Officer, and the separation of a former CEO, along with associated management continuity and compensation arrangements.
Filings also document capital markets and listing-related actions, including disclosure of Assertio’s common stock listing on The Nasdaq Stock Market LLC under the symbol ASRT and the implementation of a 1-for-15 reverse stock split of its issued and outstanding common stock. These records provide historical context for Nasdaq listing compliance and changes to the company’s capital structure.
Investors can use Assertio’s SEC filings to understand supply and product agreements, such as amendments to long-term supply contracts for Rolvedon drug substance through its subsidiary Spectrum Pharmaceuticals, Inc., including pricing terms and forecasting obligations. The filings also reference press releases that contain financial results, guidance updates, and strategic commentary.
On Stock Titan, SEC documents are paired with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify topics like quarterly performance (10-Q), annual reporting (10-K), and material 8-K events. The platform also surfaces insider and executive-related disclosures, allowing users to follow governance changes and compensation arrangements without reading every line of each filing.
Assertio Holdings, through its subsidiary Spectrum Pharmaceuticals, amended and restated its supply agreement with Hanmi Pharmaceutical for the ROLVEDON drug substance. The change, effective after the fixed pricing provisions expire in October 2025, sets long‑term pricing that includes a mid‑single digit percentage reduction to the price agreed after Assertio acquired Spectrum in 2023.
The new price remains fixed for the rest of Spectrum’s license term with Hanmi, while allowing Hanmi to request price increases for periods beginning January 1, 2028 if its costs rise above a set threshold. The amendment also adds a volume-based feature that reduces per‑gram pricing in years when the prior year’s global market volume passes a specified level. Spectrum must provide annual purchase forecasts, and at least fifty percent of forecasted orders must be binding, though there are no minimum purchase requirements. Other supply terms were not materially changed.
Assertio Holdings (ASRT) reported lower revenue and wider losses for the quarter and first half of 2025 while taking strategic steps to simplify the business. Total revenues were $29.2 million for the three months and $55.7 million for the six months ended June 30, 2025, down from $31.1 million and $63.6 million a year earlier, respectively, driven by lower INDOCIN sales despite higher ROLVEDON sales of $16.1 million in the quarter. Cost pressures included higher amortization of intangibles of $9.2 million in the quarter.
The company recorded a net loss of $16.4 million ($0.17 per share) for the quarter and $29.9 million ($0.31 per share) for the six months, which includes an $8.2 million loss on the divestiture of Assertio Therapeutics. Total assets declined to $273.8 million and shareholders' equity fell to $93.3 million. Cash and cash equivalents were $47.1 million with short-term investments of $51.1 million.
Material operational items: the Therapeutics divestiture removed Assertio from opioid-related litigation exposure but produced an $8.2 million loss; the company ceased commercialization of Otrexup (incurring $3.8 million of related costs); management recorded a $16.0 million accrual related to the Luo settlement with corresponding insurance recoverable that was later settled and reduced to zero. The company maintains $39.0 million of 6.5% convertible notes due 2027 and a full valuation allowance on deferred tax assets.
Assertio Holdings, Inc. filed a Form 8-K to report that it released its latest earnings information. On August 11, 2025, the company issued a press release announcing its financial results for the three- and six-month periods ended June 30, 2025, and furnished that release as an exhibit.
The press release is included as Exhibit 99.1, while the cover page interactive data file is provided as Exhibit 104. The company notes that the earnings information in this report is being furnished rather than filed, which affects how it is treated under securities laws and in other future SEC filings.